Long noncoding RNA SNHG6 promotes carcinogenesis by enhancing YBX1‐mediated translation of HIF1α in clear cell renal cell carcinoma

Zhao, Ping; Deng, Yu; Wu, Yong; Guo, Qinhao; Zhou, Luting; Yang, Xiaoqun; Wang, Chaofu

doi:10.1096/fj.202000732rr

Cited by 16 publications

(15 citation statements)

References 37 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, SNHG26 has significantly upregulated in bladder urothelial carcinoma and associated with poor survival ( Bao et al, 2017 ). Overexpression of SNHG6 was found to promote cell proliferation and metastasis in clear cell renal cell carcinoma (ccRCC) by interacting with YBX1 ( Zhao et al, 2021 ). These existing experimental evidence further support the predicted TIILncSig in cancer carcinogenesis and progression and immune regulation.…”

Section: Discussionmentioning

confidence: 99%

Identification and Validation of a Four-Long Non-coding RNA Signature Associated With Immune Infiltration and Prognosis in Colon Cancer

Liu

Ren

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

The emerging evidence has demonstrated the critical roles of long non-coding RNAs (lncRNAs) as regulators in the tumor immune microenvironment (TIME). However, the tumor immune infiltration-associated lncRNAs and their clinical significance in colon cancer have not yet been thoroughly investigated. This study performed an integrative analysis of lncRNA expression profiles and immune cell infiltration profiles and identified 258 immune infiltration-associated lncRNAs. Of them, four lncRNAs (AC008494.3, LINC00926, AC022034.1, and SNHG26) were significantly and independently associated with the patient’s overall survival. Finally, we developed a tumor immune infiltration-associated lncRNA signature (TIILncSig) comprising of these four lncRNAs, which can divide colon cancer patients of The Cancer Genome Atlas (TCGA) into high-risk and low-risk groups with a significantly different outcome [Hazard ratio (HR) = 2.718, 95% CI = 1.955–3.779, p < 0.001]. Prognostic performance of the TIILncSig was further validated in another independent colon cancer cohort (HR = 1.832, 95% CI = 1.045–3.21, p = 0.034). Results of multivariate Cox regression and stratification analysis demonstrated that the TIILncSig is an independent predictive factor from other clinical features (HR = 2.687, 95% CI = 1.912–3.776, p < 0.001 for TCGA cohort and HR = 1.837, 95% CI = 1.047–3.223, p = 0.034 for GSE17538 cohort). Literature analysis provided experimental evidence supporting roles of the TIILncSig in cancer carcinogenesis and progression and immune regulation. Summary, our study will help to understand the mechanisms of lncRNAs in immune regulation in the tumor microenvironment and provide novel biomarkers or targets for prognosis prediction and therapy decision-making for patients with colon cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification and Validation of a Four-Long Non-coding RNA Signature Associated With Immune Infiltration and Prognosis in Colon Cancer

Liu

Ren

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…Y-box binding protein 1 (YBX1 or YB-1) is a transcription factor, expressed at various stages of development and in early hematopoiesis [269,270] , but is also active in tumor cells [271][272][273] . Deregulation of YBX-1 in carcinogenesis seems to be attributed to a combination of epigenetic alterations and MAPK signaling [274][275][276] . Furthermore, YBX1 binds to the promoter region of ABC transporters, including ABCB1, and predicts poor outcome (reviewed in [277] ).…”

Section: Ybx1mentioning

confidence: 99%

Teaching an old dog new tricks: reactivated developmental signaling pathways regulate ABCB1 and chemoresistance in cancer

Lee¹,

Totzke²

2021

CDR

View full text Add to dashboard Cite

Oncogenic multidrug resistance (MDR) is a multifactorial phenotype intimately linked to deregulated expression of detoxification transporters. Drug efflux transporters, particularly the MDR P-glycoprotein ABCB1, represent a central mechanism by which not only chemotherapeutic drugs are extruded or sequestered to prevent drug delivery to their intracellular targets, but also for inhibiting apoptotic cell death cues, such as removal of proapoptotic signals. Several cell populations exhibiting the MDR phenotype co-exist within a tumor, such as cells forming the bulk tumor cell mass, cancer stem cells, and cancer persister cells. The key to regulation of ABCB1 expression is the cellular transcriptional machinery. Developmental signaling pathways (e.g, Hedgehog, Notch, Wnt/β-catenin, TGFβ, PITX2) are pivotal in governing cell proliferation, survival, differentiation and guiding cell migration during embryogenesis, and their reactivation during carcinogenesis, which is of particular significance for tumor initiation, progression, and metastasis, also leads to the upregulation of ABCB1. These pathways also drive and maintain cancer cell stemness, for which ABCB1 is used as a marker. In this review, the contribution of canonical and non-canonical developmental signaling pathways in transcriptional regulation of ABCB1 to confer MDR in cancer is delineated.

show abstract

“…Numerous studies have shown that cancer progression is fostered by SNHG6 [ 170 , 171 , 172 , 173 ]. Moreover, SNHG6 can elevate the expression of HIF-1α by either sponging miRNAs or enhancing the translation of HIF-1α mRNA [ 150 , 151 , 152 ].…”

Section: Lncrnas Regulating Hif-1α Expressionmentioning

confidence: 99%

“…Furthermore, the pro-tumorigenic effect of SNHG6 was also reported in clear cell renal cell carcinoma [ 152 ]. In a study concerning them, it was proposed that SNHG6 interacts with Y-box binding protein 1 ( YBX1 , also called YB1 ) and mediates the connection between YBX1 proteins and HIF-1α mRNAs to activate translation of HIF-1α transcripts [ 152 ] ( Figure 2 and Table 2 ).…”

Section: Lncrnas Regulating Hif-1α Expressionmentioning

confidence: 99%

The Hypoxia–Long Noncoding RNA Interaction in Solid Cancers

Son

Yun

Song

et al. 2021

IJMS

View full text Add to dashboard Cite

Hypoxia is one of the representative microenvironment features in cancer and is considered to be associated with the dismal prognosis of patients. Hypoxia-driven cellular pathways are largely regulated by hypoxia-inducible factors (HIFs) and notably exert influence on the hallmarks of cancer, such as stemness, angiogenesis, invasion, metastasis, and the resistance towards apoptotic cell death and therapeutic resistance; therefore, hypoxia has been considered as a potential hurdle for cancer therapy. Growing evidence has demonstrated that long noncoding RNAs (lncRNAs) are dysregulated in cancer and take part in gene regulatory networks owing to their various modes of action through interacting with proteins and microRNAs. In this review, we focus attention on the relationship between hypoxia/HIFs and lncRNAs, in company with the possibility of lncRNAs as candidate molecules for controlling cancer.

show abstract

Long noncoding RNA SNHG6 promotes carcinogenesis by enhancing YBX1‐mediated translation of HIF1α in clear cell renal cell carcinoma

Cited by 16 publications

References 37 publications

Identification and Validation of a Four-Long Non-coding RNA Signature Associated With Immune Infiltration and Prognosis in Colon Cancer

Identification and Validation of a Four-Long Non-coding RNA Signature Associated With Immune Infiltration and Prognosis in Colon Cancer

Teaching an old dog new tricks: reactivated developmental signaling pathways regulate ABCB1 and chemoresistance in cancer

The Hypoxia–Long Noncoding RNA Interaction in Solid Cancers

Contact Info

Product

Resources

About